One thing that makes me very nervous. We know that MACE reduction has a high probability of success based on the post hocs.

However, moving to 30% RRR on a 3 point MACE measure concerns me. I only hope they do not blow this because even though I believe the drug is very powerful if they hit 29% the share price will be dead once again even though the drug may be powerful AND the drug will be dead or someone will take over it's future development.

They've learned a tremendous amount about rvx-208 epigenetic effects in the past 2 years. I can only assume that the evidence is leading them to an optimal end point for success.

I feel it is going to be a very long wait but a drug that achieves double the RRR of Jardaince with an excellent safety profile, oral and low cost should be a blockbuster.

GLTA

Toinv